Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Medivation ( MDVN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Medivation fell 96 cents (-1.8%) to $52.70 on average volume. Throughout the day, 1.1 million shares of Medivation exchanged hands as compared to its average daily volume of 902,100 shares. The stock ranged in price between $51.06-$53.89 after having opened the day at $53.66 as compared to the previous trading day's close of $53.66. Other companies within the Drugs industry that declined today were: Delcath Systems ( DCTH), down 18.7%, Arrowhead Research Corporation ( ARWR), down 10.9%, Prima Biomed ( PBMD), down 10%, and Theratechnologies ( THER), down 7.7%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. Medivation has a market cap of $3.93 billion and is part of the health care sector. Shares are up 132.7% year to date as of the close of trading on Friday. Currently there are eight analysts that rate Medivation a buy, no analysts rate it a sell, and one rates it a hold.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, generally higher debt management risk and feeble growth in the company's earnings per share.

On the positive front, Cormedix ( CRMD), up 50%, Cyclacel Pharmaceuticals ( CYCC), up 22.5%, Opexa Therapeutics ( OPXA), up 18.8%, and Dyax Corporation ( DYAX), up 18.5%, were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors